Phosphatidylinositol 3-kinase (PI3K) is necessary for thyroid stimulating hormone (TSH)-induced cell cycle progression. To determine the molecular mechanism linking PI3K to TSH, we have identified a serine residue in p85a PI3K phosphorylated by protein kinase A (PKA) in vitro and in vivo. Expression of an alanine mutant (p85A) abolished cyclic AMP/TSH-induced cell cycle progression and was lethal in thyroid cells . The aspartic version of the p85a PI3K (p85D) inhibited apoptosis following TSH withdrawal. The p85a PI3K wild type not the p85A bound PKA regulatory subunit RIIb in cells stimulated with cAMP or TSH. The binding of the aspartic version of p85a PI3K to RIIb was independent of cAMP or TSH stimulation. Similarly, binding of PI3K to p21Ras and activation of AKT, a downstream PI3K target, were severely impaired in cells expressing the p85A mutant. Finally, we found that the catalytic activity of PI3K was stimulated by TSH in cells expressing the wildtype p85a PI3K but not in cells expressing p85A. This latter mutant did not affect the epidermal growth factorstimulated PI3K activity. We suggest that (1) TSHcAMP-induced PKA phosphorylates p85a PI3K at serine 83, (2) phosphorylated p85a PI3K binds RIIb-PKA and targets PKAII to the membrane, and (3) PI3K activity and p21Ras binding to PI3K increase and activate PI3K downstream targets. This pathway is essential for the transmission of TSH-cAMP growth signals.
Introduction
Stimulation of growth by cyclic AMP-protein kinase A (cAMP-PKA) in selected cell types, as in thyroid cells, is tightly dependent on Ras and Phosphatidylinositol 3-kinase (PI3K) (Kupperman et al., 1993; Al-Alawi et al., 1995; Miller et al., 1998) . Also, cAMP-PKA are powerful survival signals in all cell types tested (Affaitati et al., 2003; Wang et al., 2005) . To date, the mechanism(s) and the relevant players mediating the effects of on growth and survival are not completely known.
We have recently reported that growth of cells, NIH 3T3, normally inhibited by cAMP (Magnaldo et al., 1989; Chen and Iyengar 1994) , can be potently stimulated by cAMP if the PKA subunit RIIb is expressed in these cells (Porcellini et al., 2003) . The presence of RIIb in these lines amplified cAMP survival and transcriptional signals. We have previously shown that cAMP-PKA influence Ras signaling, by selectively stimulating the Ras-PI3K complex. Moreover, p85a PI3K is an efficient PKA substrate in vitro (Ciullo et al., 2001) .
We have identified a serine (83) in the p85a PI3K molecule that is phosphorylated in vivo and in vitro by PKA. This phosphorylation mediates the interaction of PI3K with p21Ras and estrogen receptor a (Cosentino et al., 2006) . In this work, we describe the biological consequences of the expression of mutant versions of p85a PI3K in FRTL-5 thyroid cells and in an engineered NIH 3T3 cell line that recapitulates the features of thyroid stimulating hormone (TSH)-dependent growth of thyroid cells. Our results demonstrate that phosphorylation of serine 83 is critical for TSH-dependent cell cycle progression and cell survival. Moreover, we found that phosphorylation of serine 83 by cAMP-PKA was essential for binding of p85a PI3K to the PKA regulatory subunit RIIb. We conclude that, in the presence of the RIIb-PKA subunit, abundant in cAMP-stimulated cells, p85a PI3K enucleates a complex containing PKA. Phosphorylation of serine 83 in the p85a PI3K molecule amplifies PKA binding to PI3K and stimulates the Ras-PI3K complex, which ultimately mediates survival and growth signals induced by TSH-cAMP. This pathway is essential for cAMP-dependent proliferation.
Results

p85 phosphorylation mediates TSH-dependent cell cycle progression and cell survival
Previous data from our laboratory have shown that the p85a PI3K regulatory subunit can be phosphorylated by PKA in vitro (Ciullo et al., 2001) . Sequence analysis of p85a PI3K revealed a putative PKA phosphorylation site, which was conserved in mammalian p85a PI3K . To verify that this sequence was a bona fide PKA site, we have substituted this serine 83 by alanine (p85A) or aspartate (p85D) to prevent or to mimic phosphorylation of serine, respectively. The tagged wild-type recombinant protein was phosphorylated in vivo and in vitro by PKA, whereas p85A protein was not (Cosentino et al., 2006) .
To test the biological effects of p85a PI3K phosphorylation on thyroid cell growth, we transfected the rat thyroid cell line, FRTL-5, with p85WT, p85A and p85D expression vectors. As we did not score a significant number of stable transfectants expressing p85A, we tested the plating efficiency of cells transfected with p85A or p85D. Figure 1a shows that the expression of p85A significantly reduced the number of clones of FRTL-5 cells expressing p85A. Conversely, the number of clones was significantly higher in cells expressing p85D ( Figure 1a ). These data indicate that phosphorylation of serine 83 in p85a PI3K significantly altered the growth or survival of differentiated thyroid cells. To test this notion in a defined experimental system, we used a unique cellular model that recapitulates the features of TSH-dependent growth and survival, that is, fibroblasts coexpressing the PKA regulatory subunit RIIb and wild-type TSHR under the control of an inducible promoter (NTCRII). In this model, in the absence of RIIb, activation of TSHR by TSH induced growth arrest in the presence of serum. In the absence of serum, these cells, stimulated with TSH, replicated their DNA but underwent apoptosis. Coexpression of RIIb inhibited apoptosis and stimulated the growth of the cells only in the presence of TSH or cAMP (Porcellini et al., 2003) . We have expressed p85A or p85D in these cells in the presence or absence of TSH or 8BrcAMP. Figure 1b shows that cells expressing TSHR and RIIb, which proliferated in the presence of TSH, underwent apoptosis when starved of TSH. Expression of p85WT slightly inhibited apoptosis. Expression of p85D significantly reduced the fraction of apoptotic cells starved of TSH. On the other hand, expression of p85A significantly reduced the survival of these cells in the presence of TSH. These data indicate that phosphorylation of serine 83 amplifies the transmission of survival signals by TSH and PKA, and explain the low survival rate of thyroid cells expressing p85A ( Figure 1a) .
To analyse more precisely the biological effects of p85A or p85D on cycle progression and growth of TSHRIIb-expressing cells, we carried out a detailed cell cycle analysis by performing 5-bromodeoxyuridine (BrdU) pulse-chase labeling experiments. In low serum, TSH induced DNA synthesis and stimulated S and G2-M transition in cells expressing p85WT or control plasmids (Figure 1c) . Expression of p85A resulted in a significant accumulation of cells in S phase. Note that in 270 min, control cultures exit S phase and accumulated in G2 M. Expression of p85D did not significantly alter cell cycle progression ( Figure 1c ). We have also tested if the expression of p85A or p85D mutants altered cell cycle progression or proliferation induced by epidermal growth factor (EGF). Supplementary Figure 1S shows that the growth rate and cell cycle progression induced by EGF or serum (not shown) were not affected by the expression of p85a PI3K mutants. These experiments indicate that inhibition of phosphorylation of p85a PI3K at serine 83 slows down S-G2/M progression induced by TSH-cAMP.
Phosphorylation of serine 83 in p85a
PI3K is required for TSH-induced AKT phosphorylation As p85A inhibited cell cycle transitions induced by TSH, we tested whether the signaling cascade triggered by TSH or cAMP was impaired. cAMP and TSH stimulated PKA, which can directly phosphorylate AKT (Sable et al., 1997; Filippa et al., 1999) and/or induce the recruitment of PI3K to the membrane (Suh et al., 2003) . We determined the phosphorylation of AKT in cell lines expressing p85WT or p85 mutant in the presence or absence of TSH. The ratio P-AKT/total AKT, a rather accurate index of AKT activation, was determined. Cells expressing p85WT, the p85A mutants or p85D mutants were stimulated with TSH for various periods of time and tested for AKT phosphorylation. Figure 2 shows that TSH induced AKT phosphorylation and that in cells expressing p85A, AKT induction was almost completely abolished. Both FRTL-5 ( Figure 2a ) and NTCRII cells (Figure 2b ), expressing p85A, were unable to activate AKT in the presence of TSH. The expression of p85D did not significantly affect the absolute level of AKT activation by TSH, but modified the kinetics of activation in both cell lines (Figure 2a and b) . Induction of P-AKT by EGF was not affected in cells expressing both mutants (Supplementary Figure 2S ). Pretreatment with a PKA inhibitor H89 (10 mM) abolished TSH-induced AKT phosphorylation (data not shown). These data indicate that serine 83 in p85a PI3K is important for TSH induction of AKT.
Phosphorylation of serine 83 influences the formation of PKA-PI3K and Ras-PI3K complexes The p85A mutant induced apoptosis, inhibited cell cycle progression and prevented AKT phosphorylation by TSH in thyroid and NTCRII cells. Both cell lines were exquisitely dependent on TSH and cAMP for growth. As in these cells the expression of PKA subunit RIIb conferred TSH-and cAMP-dependent growth (Porcellini et al., 2003) , we tested whether p85a PI3K formed a complex with RII-PKA. The RIIb-p85a PI3K complex was assayed by a p85 pull-down assay, using the glutathione S-transferase (GST)-RIIb fusion protein as bait (Grieco et al., 1996) . The binding assay was carried out with extracts derived from NTCRII cells transiently transfected with the p85WT, p85A, p85D or with the p85 mediates TSH-PKA growth and survival signals G De Gregorio et al empty vector (control) and from FRTL-5 clones stably transfected with the same p85a PI3K vectors. FRTL-5 cells were derived from the few clones expressing low levels of p85A, as shown in Figure 1a . Figure 3a shows that phosphorylated p85WT binds the PKA type II regulatory subunit RIIb in a TSHdependent manner. TSH treatment (10 mU/ml) for a period of 10 min induced the formation of the complex or p85D treated without (white bar) or with TSH (gray bar) or 8BrcAMP (black bar). Cells were transiently transfected with the constructs indicated above. At 18 h after induction with 0.5% serum in the presence of TSH or cAMP, cells were subjected to TUNEL assay as described in Materials and methods. Inset: Western blot analysis with anti-p85 PI3K antibody to verify that expression of the constructs was comparable in the different samples. (c) Cell cycle progression of cells expressing p85WT, p85A or p85D. NTCRII cells were transiently transfected with the p85WT, p85A, p85D mutants or with the empty vector (control). At 24 h after transfection, the cells were serum starved for 18 h and induced with 10 mU/ml TSH in the presence of 0.5% serum. BrdU incorporation was assayed by a pulse-chase experiment. Cells were labeled for 30 min with BrdU and harvested at 0, 90 and 270 min. Cells were subjected to fluorescence-activated cell sorting (FACS) analysis for bivariate analysis of DNA content versus BrdU. to RIIb was observed after cAMP treatment (100 mM 8BrcAMP) (Figure 3c ). Conversely, the p85D mutant was bound to RIIb even in the absence of cAMP or TSH (Figure 3a and c). We also detected bound p85a PI3K phosphorylated at serine 83 with anti-phosphoserine antibodies in p85WT, isolated from cells stimulated with TSH ( Figure 3a ). Most notably, the binding of p85D to RIIb was resistant to the PKA inhibitor H89 (Figure 3c ) and, as expected, it was not present in the immunoblot probed with anti-phosphoserine antibody (Figure 3a) . To demonstrate a direct interaction of RIIb-p85a PI3K , NIH 3T3 cells were transiently transfected with p85WT or p85A and treated for 60 min with 100 mM 8BrcAMP. Exogenous p85a PI3K was immunoprecipitated with anti-FLAG antibody, extensively washed in RIPA buffer containing 1% Triton X-100À0.1% sodium dodecyl sulfate (SDS) and purified by elution with 0.1 M glycine (pH 3.5). Purified p85a PI3K was then incubated in vitro with GST-RIIb and a pull-down experiment was repeated, as described above. Figure 4 shows that p85WT binds GST-RIIb but not control GST. Moreover, the binding of p85a PI3K to RIIb was stimulated by pretreating the cells with cAMP ( Figure 4 ). The p85A mutant did not bind RIIb, both in the presence and absence of cAMP. Collectively, these data demonstrate that p85a PI3K upon phosphorylation of serine 83 induced by cAMP or TSH binds PKA via the regulatory subunit RIIb. Proximity of PKA to PI3K may favor signaling of both kinases to downstream effectors.
We have previously shown that cAMP-PKA selectively increased the association between PI3K and p21Ras (Ciullo et al., 2001) . As this complex may mediate the cytoprotective effects of cAMP-PI3K, we set out to determine the formation of p21Ras-PI3K in cells expressing wild type or the mutant versions of p85a PI3K indicated above. NTCRII cells were transfected with p85WT, p85A or p85D, and after 36 h, the cells were serum starved for 16 h before treatment with TSH for 10 min. Cell lysates were immunoprecipitated with anti-FLAG antibody and then analysed by Western blot with anti-p85a PI3K and anti-Ras antibodies. In the presence of TSH, p85a PI3K efficiently associated with p21Ras in p85WT-expressing cells. This association was greatly reduced in cells expressing p85A. In the absence of TSH, Ras association with p85a PI3K was barely detectable in p85WT-and p85A-expressing cells. Conversely, the association of the mutant p85D to p21Ras was present in the absence of cAMP, but it was also stimulated by cAMP ( Figure 5 ). The same results were obtained in FRTL-5-transfected clones ( Figure 5) .
We conclude that phosphorylation of p85a PI3K binds RIIb in a cAMPdependent manner in NTCRII cells. Immunoblot analysis of p85 PI3K bound to RIIb in transiently transfected NTCRII cells. Cells were starved of serum for 6 h (0.5% serum) and exposed to 100 mM 8BrcAMP for 15 min with and without 10 mM H89. PI3K was immunoprecipitated with anti-FLAG antibody from NTCRII cells transfected with p85WT or p85A, and exposed to 100 mM 8BrcAMP for 15 min. The immunoprecipitate was extensively washed in RIPA buffer containing 1% Triton X-100 À0.1% SDS and purified by elution with 0.1 M glycine pH 3.5. Input indicates the eluted fraction; ( þ ) glycine represents the pellet after elution. The purified p85 PI3K was incubated in vitro with GST-RIIb in a pull-down experiment as described in Materials and methods.
p85 mediates TSH-PKA growth and survival signals G De Gregorio et al mutant, p85A, inhibited these interactions and downstream PI3K signaling, such as AKT phosphorylation.
To test if phosphorylation of serine 83 in p85a
PI3K
influenced the catalytic activity of PI3K, we performed PI3K enzymatic assays on immunoprecipitated p85a PI3K . Figure 6 shows that TSH stimulated PI3K activity, although less efficiently than EGF, and that p85A inhibited TSH induction. To test if p85A inhibited PI3K activity per se, independent of the specific signaling pathway involved, we tested EGF-induced PI3K in cells expressing p85A or p85D. Figure 6B shows that PI3K activity induced by EGF was sensitive to the specific PI3K inhibitor LY294002 and that expression of p85A or p85D did not influence EGF-induced activity.
These data indicate that phosphorylation of serine 83 in p85a PI3K selectively influences TSH-or cAMP-induced PI3K activity.
Discussion
The data presented demonstrate the importance of p85 PI3K in the transmission of TSH and cAMP growth and survival signals. Specifically, phosphorylation of serine 83 in the p85a PI3K is essential for the binding of PI3K to PKA. We suggest that following PKA anchoring to PI3K, p21Ras associates to the complex and PI3K catalytic activity is greatly stimulated. Mutagenesis of this site profoundly and selectively impaired the transmission of TSH signals by disrupting this complex. EGF (Supplementary Figure 2S and Figure 6 ) or PDGF stimulation of PI3K (Cosentino et al., 2006) was not influenced by the substitution of serine 83 by alanine or aspartate in p85a PI3K . The stimulation of PI3K catalytic activity by cAMP-TSH was evident in the absence of serum (see also, Porcellini et al., 2003) and was dependent on the phosphorylation of serine 83 in p85a PI3K . However, the aspartic mutant of serine 83 p85a PI3K replicated cAMP effects on (i) the inhibition of apoptosis by TSH starvation and (ii) the binding to PKA. It amplified cAMP effects on (i) PI3K activity, (ii) AKT phosphorylation and (iii) the efficiency of formation of the complex PI3K-p21Ras. These data indicate that serine 83 phosphorylation of p85a PI3K is necessary but not sufficient to stimulate PI3K, phosphorylation of AKT and formation of the p21Ras-PI3K complex. Functional PKA is indeed required for these cAMP effects. As PKA binding to p85D is H89-resistant (Figure 3c ), phosphorylation of serine 83 in p85a PI3K is necessary and sufficient for PKA anchoring to PI3K. This is a non-redundant circuit in thyroid or cells expressing TSHR and PKAIIb, because its elimination profoundly impaired survival and growth. In contrast, in cells containing low levels of cAMP and RIIb, the expression of p85A abolished only cAMP response, with a marginal effect on survival (data not shown; Cosentino et al., 2006) . As for the mechanism, the data presented indicate that the serine 83 in p85a PI3K is a critical site for the transmission of receptor signals to PI3K. The alanine mutant inhibits cAMP effects on PI3K activity. It is possible that a conformational change induced by phosphorylation is important for stimulation of PI3K activity. It is noteworthy that substitution of serine 83 by aspartate in p85a PI3K stabilizes the complex with p110 (Cosentino et al., 2006) .
We wish to stress that these data highlight a general role of serine 83 in the p85a PI3K molecule in the transmission of cAMP signals in many cell types. We have recently found that many independent signaling pathways that stimulate cAMP converge on this site. For example, p85A disrupts the binding of PI3K to estrogen receptor and inhibits AKT activation by estrogens (Cosentino et al., 2006) .
We suggest that phosphorylation of serine 83 by cAMP-PKA induces a conformational change in the PI3K complex, resulting in facilitated binding to receptors and to p21Ras, with stimulation of PI3K activity. We believe that this site is a nodal point where information from several receptors is channeled to PI3K.
Materials and methods
Materials and reagents
Unless otherwise specified, drugs and chemicals were obtained from Sigma Aldrich (St Louis, MO, USA) and cell culture supplies were purchased from standard suppliers, for example, Falcon, BD Biosciences, San Jose, CA, USA; GIBCO-Life Figure 5 Phosphorylation of serine 83 selectively influences the formation of Ras-PI3K complex. The p21Ras-p85a PI3K complex was assayed by immunoprecipitation with anti-FLAG antibodies and immunoblotting with anti-pan-Ras antibodies. NTCRII cells were transiently transfected with p85WT, p85A, p85D or with the empty vector. FRTL-5 cells were the stable clones indicated in Figure 1 . Cells were starved of serum for 6 h (0.5% serum) and exposed to 10 mU/ml TSH for 20 min. Figure 1 . At 48 h after transfection, cells were serum starved and maintained in low serum (0.2%) for 8 h. Cells were treated with TSH (10 mU/ml) or EGF (100 ng/ml) for 20 min. p85-FLAG was immunoprecipitated (IP) with the anti-FLAG M1 affinity gel and the immune complexes were subjected to PI3K lipid kinase assays as described in Materials and methods. Technologies, Invitrogen S.R.L, San Giuliano Milanese (MI), Italy, HyClone, Logan, UT, USA.
Cell lines
Mouse fibroblasts NIH 3T3 were grown in Dulbecco's modified Eagle's medium containing 10% fetal calf serum and 2 mM glutamine (standard medium). The tTA repressorexpressing clones were grown in standard medium containing puromycin 2.5 mg/ml puromycin, 1.0 mg/ml tetracycline and 200 mg/ml geneticin (G-418). The selection and tetracycline were removed 48 h before starting the experimental procedures described below. The FRTL-5 cell line is a thyroid cell line, which has been extensively characterized with respect to thyroglobulin expression and TSH-dependent growth (Ambesi-Impiombato et al., 1980). Cells were grown in F12 medium with 5% calf serum and six hormones (1 mU/ml TSH, 1 mg/ml insulin, 3.6 mg/ml hydrocortisone, 5 mg/ml transferrin, 10 ng/ml somatostatin, 20 mg/ml glycyl-histidyl-lysine). FRTL-5 clone expressing the p85 variants was generated by transfecting FRTL-5 cells with the pSG5-p85 vectors. Neomycin-resistant clones were isolated and characterized for NEO and p85 expression by Western blots.
Plasmid construction
The p85a PI3K plasmids have been described by Cosentino et al. (2006) . Briefly, p85 cDNA was subcloned in pSG5 vector. FLAG sequence was added by subcloning into the XhoI/ BamHI sites of the pSG5-p85 vector a PCR fragment spanning from the XhoI site of p85 PI3K at position 1014 to the end of the fragment. The vector encoding for p85-FLAG was then used as a template of PCR for site-directed mutagenesis (QuickChange Site-Directed Mutagenesis Kit, Stratagene, Cedar Creek, TX, USA) to convert serine 83 to alanine.
Transfections
The day before transfection, cells were plated at 60% confluence in 100 mm dishes and transfected with 2 (NTCRII) or 8 (FRTL-5) mg/dish of p85WT, p85A, p85D or empty vector using 2.75 or 12.5 ml/mg DNA of Lipofectamine Plus (Invitrogen, Carlsbad, CA, USA). Following 5 h of exposure to lipofectamine, the cells were washed and grown for 36-48 h before assays.
Cell growth analysis
Proliferation was analysed under different conditions: normal medium or low serum (0.5%) with and without 10 mU/ml TSH or 25 ng/ml EGF. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) colorimetric assay for proliferation was performed in a 96-well flat-bottomed tissue culture tray for each time point: 1500 cells for each clone were seeded in eight replicas for each experimental point; 6 h after plating, the standard medium was removed and 100 ml of culture medium with stimuli as indicated was applied. The determinations were carried out every 24 h as follows: 0.01 ml MTT stock (5 mg/ml) was added to each well, then after 4 h of incubation at 371C, the medium was removed and 0.1 ml isopropanol/ 0.04 N HCl was added. The absorbance was measured after 1 h on an enzyme-linked immunosorbent assay plate reader. We have used a Dynatech MR580 reader with a test wavelength of 570 nm and a reference wavelength of 630 nm.
Western blot
Cells were transfected as indicated above. After 48 h, cells were exposed to 10 mU/ml TSH, 100 mM 8BrcAMP or 100 ng/ml EGF, harvested at times indicated and lysed on ice-cold RIPA buffer (1% Triton X-100, 0.5% sodium deoxycholate (DOC), 0.1% SDS, 50 mM Tris-HCl pH 7.6, 150 mM NaCl, 1 mM phenylmethylsulfonyl fluoride, 1 mg/ml aprotinin, leupeptin and pepstatin). After centrifugation at 12 000 g, protein concentrations were determined. Fifty micrograms of protein was subjected to 7 or 12% SDS-polyacrylamide gel electrophoresis and transferred onto nitrocellulose membranes (Schleicher and Schuell, Whatman plc, Brentford, Middlesex, UK, Germany). Western blot analysis was carried out by using the appropriate antibody as noted in the figures. The anti-p85 was from Upstate-Millipore (Billerica, MA, USA) (#06-497). The anti-pan-Ras antibody was from Calbiochem (affiliate of Merck KGaA, Darmstadt, Germany) (EMD Biosciences Inc., an affiliate of Merck KGaA, Darmstadt, Germany). The antibody against Akt and phospho-Akt were from Cell Signaling Technology (Beverly, MA, USA). The horseradish peroxidase-conjugated anti-rabbit and anti-mouse secondary antibodies and the ECL detection system were from Amersham Pharmacia Biotech Italia (Milano, Italy).
Pull-down and immunoprecipitation
Cells were lysed in pull-down buffer (200 mM NaCl, 50 mM Tris-HCl pH 7.5, 2 mM MgCl 2 , 10% glycerol, 1% NP-40, 10 mg/ml trypsin inhibitor, 1 mg/ml aprotinin, 1 mg/ml leupeptin, 10 mM NaF, 10 mM Na 3 VO 4 ). The cell extracts (1 mg) were incubated with 1 mg of GST-HRIIb fusion protein for 4 h at 41C with gentle rock agitation. The pellets were washed in pulldown buffer and processed for Western blot analysis as described.
Total extracts for immunoprecipitation were prepared by incubating cells on ice with RIPA buffer containing 1 mM ethylene diaminetetraacetic acid. Cell lysates (1 mg) were incubated with 2 mg of normal mouse IgG (sc 2025) and 25 ml of protein A Sepharose (Amersham Pharmacia Biotech, Piscataway, NJ, USA) for 1 h at 41C. After centrifugation, protein lysates were incubated with 4 mg of anti-FLAG M1 affinity gel (Sigma A4596) for 4 h at 41C on a rocking plate. The pellets were washed with RIPA buffer and processed for Western blot analysis as already described. The fusion protein was eluted by using 0.1 M glycine HCl pH 3.5 and neutralized with 1 M Tris-HCl pH 8.
Analysis of DNA content and BrdU incorporation
Cell cycle analysis was carried out by fluorocytometric absorbent cell sorter (FACS): 5 Â 10 5 transfected cells (48 h after transfection) were plated in 60 mm dishes and grown in low-serum medium (0.5% fetal bovine serum) for 18 h and induced into the cell cycle with 0.5% serum in the presence of 10 mU/ml TSH or 100 ng/ml EGF. BrdU incorporation was assayed in a pulse-chase experiment. Cells were labeled for 30 min with BrdU to a final concentration of 20 mg/ml and harvested at 0, 90 and 270 min. After treatment, cells were fixed in 70% ice-cold ethanol for 4 h at 41C and washed three times in phosphate-buffered saline (PBS). Cell pellet was resuspended in 0.25 ml of 1 N HCl and let to stand for 20 min at room temperature (RT). After acidic denaturation of DNA, cells were washed two times in phosphate/citric buffer (0.2 M Na 2 HPO 4 , pH 7.4). BrdU incorporation was revealed by antiBrdU-FITC (Becton Dickinson, Franklin Lakes, NJ, USA) and then stained for 30 min at RT in 0.1% Triton X-100, 0.2 mg/ml DNase-free RNaseA and 20 mg/ml propidium iodide. Fluorescence was determined by using the FACScan Flow Cytometer (Becton Dickinson). Experiments were performed in triplicate. The data were acquired and analysed by CELLQuest software (Becton Dickinson) for bivariate analysis of DNA content versus BrdU and by Cell Fit CellCycle Analysis Version 2 for DNA content analysis. Apoptosis assay 5 Â 10 5 cells were grown in 60 mm dishes. At 18 h after treatment, cells were fixed in 2% paraformaldehyde/1 Â PBS for 10 min at RT and washed once in PBS þ 50 mM glycine for 10 min at RT and washed again three times for 5 min in PBS. Cells were permeabilized with 0.5% Triton X-100/1 Â PBS for 10 min, washed 3 Â 5 min in PBS and incubated with 100 ml of 1 Â TdT reaction mix. TdT-mediated dNTP nick end labeling was carried out at 371C for 60 min using 15 U of TdT (Roche Diagnostics S.p.A, Roche Applied Science, Monza, Italy) and 2 ml of 2 mM BrdUTP. BrdUTP incorporation was revealed by anti-BrdU-FITC and then stained with propidium iodide. The data were acquired and analysed by CELLQuest software for bivariate analysis of DNA content versus BrdU. Experiments were performed in triplicate.
Lipid kinase assay Lipid kinase activity was determined as described by Maier et al. (1999) . Briefly, the assays were carried out in a final volume of 50 ml containing 0.1% bovine serum albumin, 1 mM ethylene glycol-bis (b-aminoethylether) tetraacetic acid, 120 mM NaCl, 40 mM HEPES, pH 7.4, 1 mM dithiothreitol, 1 mM glycerophosphate and 7 mM MgCl 2 (buffer E). Lipid vesicles (30 ml containing 320 mM phosphatidylethanolamine, 300 mM phosphatidylserine, 140 mM phosphatidylcholine and 30 mM sphingomyelin, supplemented with 40 mM L-a-Phosphatidylinositol-4,5-bisphosphate (PI-4,5-P2) in buffer E) were sonicated for 1 h and incubated on ice for 10 min. Some aliquots were preincubated with 0.5 mM LY294002 (Calbiochem) at 371C. The immunoprecipitates were added to the lipid mixture and incubated for 10 min at 41C in a final volume of 40 ml. The reaction was started by adding 40 mM ATP (1 mCi of [ 32 P]ATP in 10 ml of the assay buffer (301C)). After 15 min, the reaction was stopped with ice-cold 150 ml of 1 N HCl on ice. The lipids were extracted by vortexing the samples with 500 ml of chloroform/methanol (1:1). After centrifugation, the organic phase was washed twice with 200 ml of 1N HCl. Phosphorylated lipids were separated on a potassium oxalate-pretreated thin-layer chromatography plates (silica gel 60 Merck) developed in CHCl 3 /CH 3 OH/H 2 O/NH 4 OH (60:47:11.3:2), dried, and visualized by autoradiography and quantified with Phosphor-Imager.
